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Aim: To study the effect of new vasopressin V1b receptor antagonist, SSR149415, on anxiety-like behavior and Lewis lung carci-
noma metastasis in the anxious adult male mice of C57Bl/6J strain. This type of receptors was thought to act as potential targets 
mediating the effect of negative psychoemotional state on tumor progression. Methods: Anxiety-like psychoemotional state of the 
animals was produced using chronic social conflict model. Used behavioral tests were elevated plus-maze, social interaction test and 
open field test. Tumor cells were administrated on background of double or sixfold SSR149415 injections and the number of me-
tastases in the lung were calculated 17 days later. Results: SSR149415 reduced the anxiety-like behavior measured in the elevated 
plus-maze and social interaction tests and did not affect locomotor activity in the open field test. Double and sixfold administration 
of the compound to such mice before and after inoculation of the tumor cells produced no effect on the metastasis rate. Conclusion: 
vasopressin V1b receptor is involved in the mediation of anxious behavior of animals but is not involved in the mechanism underlying 
the influence of negative psychoemotional state on Lewis lung carcinoma metastasis.
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The effect of psychoemotional state on tumor pro-
gression is an established phenomenon although its 
underlying mechanisms remain elusive. Three decades 
ago it was demonstrated that rearing of animals in over-
crowded conditions and subsequent activation of the 
stress system of organism can significantly change the 
incidence of tumors and the number of tumor metastatic 
nodules [22]. The study of two types of transplantable 
tumors carried out in mice showed that animals with 
anxiety-like behavior induced by rearing in stressful 
conditions have twice as much of experimental me-
tastases as intact mice [10, 16], while anxiolytic drug 
diazepam reduces the number of metastases [9].
Hypothalamic hormone vasopressin potentiating 
the action of corticoliberin can increase the secretion 
of the adrenocorticotropic hormone and subserves 
significantly to the formation of negative stress-
induced psychoemotional states [13, 23]. Distribution 
of vasopressinergic fibers and receptors in the limbic 
structures of the brain suggests the involvement of this 
neuropeptide in emotional responses to stress [11]. 
The animals with depression semiotics and patients 
with major depression were shown to have an in-
creased plasmatic level of vasopressin. In both cases 
administration of antidepressants normalizes the 
hormone level [4, 12]. Rats selected for high anxiety 
behavior exhibit innate elevated expression of vaso-
pressin mRNA and hypothalamic receptor binding [18]. 
Exogenous intraventricularly administered vasopres-
sin produces anxiogenic effect while its antagonists 
alleviate the symptoms of anxiety [2, 7]. Clinically ef-
fective anxiolytic drugs reduce the expression of the 
vasopressin precursor gene [23]. 
In the experiments with Lewis lung carcinoma (LLC) 
metastasis, administration of vasopressin was shown 
to increase the number of metastatic nodules in the 
lungs of mice [1], similarly as it occurs in animals with 
an impaired psychoemotional state. Still it is so far not 
clearly how the mechanisms of vasopressin action 
on metastasis and psychoemotional state interrelate.
Physiological action of vasopressin is known 
to be mediated by receptors of three types: V1a, V1b, 
and V2. The receptors of the former two types are 
widespread in the CNS structures [8, 20] and are in-
volved in anxious behavior [5]. Receptors of V1a type 
are also present on unstriped muscles of the brain 
vessels and V1b receptors — on corticotroph pituitary 
cells to implement the effect of vasopressin on the 
stress axis of organism [21]. Receptors of both types 
are sensitive to emotional stress. Anxiety-like behav-
ior in animals correlates with enhanced V1-receptor 
binding in the CNS [12]. Addition of antisense mRNA 
of V1a receptor to mice results in a pronounced allevia-
tion of anxiety-like behavior and impairment of social 
recognition. Chronic immobilization stress increases 
V1a mRNA level in rat brain [17].
Recently synthesized specific vasopressin V1b-
receptor antagonist, SSR 149415 [7] provides the 
opportunity for distinguishing the contribution of re-
ceptors of this type to increasing of tumor metastasis 
in animals with pronounced anxiety-like behavior, 
which has become the purpose of this study.
matEriaLs and mEthods
Animals. Male C56B1/6J strain mice, weigh-
ing 25–28 g, housed in standard conditions of the 
vivarium of the Institute of Cytology and Genetics, 
Siberian Branch of the Russian Academy of Sciences 
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were used. All experimental procedures with animals 
were carried out in accordance with the international 
rules established by the European Community Council 
Directive (86/609/EEC).
Anxious pattern of mice behavior was produced 
using a 10-day chronic social conflict model [15].
Behavior Evaluation Methods
The elevated plus-maze (EPM). This method 
is used to measure anxiety-like behavior of the mice 
placed in unfamiliar environment [24]. The four-minute 
experimental sessions were recorded with video 
camera. The conventional behavioral measures were 
recorded with the use of the “Mouse” software pack-
age (Institute of Cytology and Genetics, SB RAS). The 
most significant anxiety-related measures included 
time spent in the central area of the maze, time in the 
closed arms and time in the open arms and area (sum 
of central area and open arms times), and latent period 
of closed-arm entries. Exploratory behavior measures 
were the number of dipping postures with head below 
the level of the maze and stretching postures.
The “Partition” social interaction test. This test 
is used to obtain quantitative measures of sociability 
(communicativeness) of the animals relative to the 
level of anxiety [6]. The behavior of the mice in anxiety-
like state was assessed in response to a known aggres-
sive male and a strange male placed by turns in the 
neighboring compartment of the home cage across 
a perforated transparent partition. During the 6-minute 
test periods (3+3), the number of approaches and time 
at the partition were recorded for the test male and the 
derived measure — average time at the partition per 
approach — was calculated as an indirect measure 
of communicative motivation of the mice.
Open field test. This test is used to evaluate lo-
comotor and exploratory activities. Three-minute test 
sessions were recorded with video camera. The be-
havior of the mice was recorded and calculations were 
made to find the distance, average speed, immobility 
time, number of upright postures and explorations 
of the setting holes as well as the time in the central 
and peripheral zones of the setting. 
Oncological Experiments. Lewis lung carcinoma 
cells were inoculated into the tail vein (0.5 ml of sus-
pension, 170 thousands cells/mouse). Seventeen days 
later the mice were decapitated; the lungs were fixed 
in 10% formalin solution. The number of metastatic 
nodules was calculated under a microscope with 8-fold 
magnification. Two experiments were performed:
double administration of SSR149415 — a day be-
fore and on the day of the tumor cell inoculation;
sixfold administration of SSR149415 — once a day 
during 6 days. Tumor cells were inoculated on the 
fourth day of SSR149415 injections.
Pharmacology. Vasopressin V1b receptor an-
tagonist, SSR149415, (10 mg/kg, suspended in 0.6% 
methylcellulose and 0.5% Tween solution) was admin-
istrated once 1 hour before the behavioral tests. Also, 
in the day of tumor cell inoculation, the compound was 
administrated 1 hour before LLC cell injection too. Since 
the drug is known to be equally active at intraperitoneal 
and oral administration [7], both methods were used 
in our experiments. The vehicle in equal volumes was 
administered by the same methods to control mice.
Statistical Processing. The results were analyzed 
with the use of Student’s t-criterion using STATISTIKA 
6.0 software package. Each experimental group con-
sisted of 11–15 animals.
rEsuLts
Behavioral tests
Elevated plus-maze. Intraperitoneal adminis-
tration of SSR149415 significantly reduced the level 
of anxiety-like behavior in animals (Table 1). The mice 
spent almost twice as less time in the EPM closed arms 
and thrice as much time in the open areas as compared 
to control. The latent period for entries into the closed 
arms also grew significantly. The time of staying in the 
center of the maze increased 2.5 times versus the con-
trol, which could be interpreted as a reduced speed of 
“decision making” on the backdrop of the drug action. 
Exploratory activity measures — dipping postures with 
heads below the maze and stretching postures showed 
no reliable difference from the control values mainly 
due to a considerable scattering of data.
Table 1. Effect of vasopressin receptor antagonist, SSR149415, on the be-
havior of male mice with anxiety-like behavior in elevated plus-maze test
Anxious animals 
+ vehicle (15)
Anxious animals + 
SSR149415 (13)
Time in closed arms, sec 195.53 ± 13.96 109.92 ± 25.11 **
Latent period of closed arm entry, sec 19.20 ± 7.31 78.46 ± 25.50 *
Time in open arms, sec 5.60 ± 2.73 29.69 ± 18.06
Time in the center of the maze, sec 38.00 ± 13.34 97.77 ± 22.90 *
Time in open areas, sec 43.60 ± 13.76 127.46 ± 25.85 **
Number of dipping postures 2.87 ± 0.82 5.46 ±1.14
Number of stretching postures 0.73 ± 0.41 2.69 ± 1.00
Note. *р<0.05; **p<0.01 compared to animals with anxiety, administra-
tion of the vehicle.
“Partition” social interaction test. Oral adminis-
tration of SSR149415 produced no effect on the main 
measure of communicativeness — time spent by the 
mice at the partition exploring the smell of a male 
placed in the neighboring compartment (Table 2). 
Nonetheless, the drug administration to male mice 
with anxiety-like symptoms in the situation with unfa-
miliar male behind the partition doubled the derived 
measure — the time at the partition per approach — 
as compared to control mice suggesting an enhance-
ment in mice motivation for communication with 
a conspecific and reduction of anxiety-like behavior 
following the administration of SSR149415.
Table 2. Effect of vasopressin receptor antagonist, SSR149415, on the be-
havior of male mice with anxiety-like behavior in the social interaction test
Anxious animals 
+ vehicle (15)
Anxious animals + 
SSR149415 (11)
Familiar male:
Number of interactions (N)
Time of interactions (T), sec
Average interaction time (T/N), sec
4.23 ± 0.43 3.90 ± 0.85
41.31 ± 7.73 38.70 ± 6.12
9.69 ± 1.59 12.44 ±2.30
Unfamiliar male:
Number of interactions 4.13 ± 0.75 3.09 ± 0.77
Time of interactions, sec 67.47 ± 12.17 69.73 ± 10.79
Average interaction time, sec 17.37 ± 1.72 34.76 ± 8.15 *
Note. *р<0.05; **p<0.01 compared to animals with anxiety-like behavior 
receiving the vehicle.
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Open field test. Oral administration of SSR149415 did 
not affect locomotor or exploratory activity of animals 
with anxiety-like behavior in the test (Table 3).
Table 3. Effect of vasopressin receptor antagonist, SSR149415, on the 
behavior of male mice with anxiety-like behavior in open field test
Anxious animals 
+ vehicle (15)
Anxious animals + 
SSR149415 (11)
Passage distance, cm 290 ± 37 308 ± 42
Immobility time, sec 49.3 ±10.4 62.4 ± 9.6
Speed (distance/time in motion, cm/sec) 2.2 ± 0.2 2.5 ±0.3
Time in the central area, sec 50.2 ± 10.2 36.0 ± 7.4
Time in peripheral area, sec 130.8 ± 10.1 142.2 ±7.6
Number of holes explored 6.4 ± 1.1 5.3 ± 1.1
Number of vertical postures 3.1 ± 0.7 2.7 ± 0.7
metastasis
As a rule, the number of LLC metastatic nodules 
in the lungs positively correlates with the level of anxiety 
in animals. In our experiments this correlation was reli-
ably reproduced in the second experiment (Table 4).
Table 4. Effect of vasopressin receptor antagonist, SSR149415, on me-
tastasis of Lewis lung carcinoma in the lungs of male mice with anxiety-
like behavior
Number of meta-
static nodules
Experiment 1: Intact animals + vehicle 9.9 ± 1.7 (14)
Animals with anxiety-like behavior + vehicle 12.8 ± 1.34 (15)
Animals with anxiety-like behavior + SSR149415 14.54 ± 1.93 (13)
Experiment 2: Intact animals + vehicle 8.2 ± 1.3 (11)
Animals with anxiety-like behavior + vehicle 14.7 ± 2.2 (15) *
Animals with anxiety-like behavior + SSR149415 15.0 ± 2.2 (14)
Note *р<0.05 as compared with intact animals receiving the vehicle.
In the first experiment, after double intraperitoneal 
administration of SSR149415 to mice with anxiety-like 
behavior the number of metastatic nodules did not 
change as compared with administration of vehicle 
to control group.
In the second experiment, after six oral administra-
tions of SSR149415 the number of metastatic nodules 
did not differ from control values.
discussion
Possible influence of emotional state of an indi-
vidual on the course of tumor progression has been 
of interest exclusively for practicing psychologists 
[3, 25]. In the literature under discussion is whether 
and to what degree psychotherapy can influence the 
treatment of patients with tumors. The opinions on this 
topic seem to be equally divided. We failed to find any 
biochemical studies aiming to elicit the correlation 
between psychoemotional state of patients (includ-
ing the activity of hypothalamus-pituitary-andrenal 
axis and vasopressinergic systems) and the efficacy 
of anticancer therapy.
The studies of the last decade demonstrated that 
vasopressin is a principal regulator of emotional be-
havior. Studies in humans support the co-activation 
of the central vasopressinergic system at anxiety 
and depression disorders [23] while clinically effec-
tive anxiolytic drugs and antidepressants reduce the 
expression of the vasopressin gene in the CNS [4]. 
It is vasopressin that provokes hyperactivation of the 
hypothalamus-pituitary-adrenal axis under chronic 
emotional stress by acting on pituitary corticotrophs 
through V1b receptors [14]. 
The leading role of vasopressin in behavioral 
phenomena of anxiety and depression and in stress-
induced diseases was also demonstrated on animal 
models [18]. The Brattleboro rates deficient for vaso-
pressin gene demonstrate elements of depression-like 
behavior [19]. In our experiment with mice a single 
subcutaneous administration of vasopressin caused 
behavioral reactivity of animals in the open field test [1]. 
In our experiments anxiety-like behavior was 
formed during 10 days by means of daily 10-minute 
agonistic interactions with a stronger male who was 
kept during the rest of the day in the neighboring 
compartment of the cage behind a perforated trans-
parent partition. This procedure is sufficient to form 
a stable anxiety-like state in experimental animals 
[15]. Administration of V1b receptor antagonist, 
SSR149415, resulted in a visible reduction of anxiety 
level in the elevated cross-maze test and an increase 
of motivation in animals with anxiety-like behavior for 
social interaction with a strange male in the partition 
test. Therefore, in our experiments we reproduced the 
results confirming the anxiolytic effect of the drug [7]. 
After injection of vasopressin antagonist no changes 
in locomotor activity were recorded.
Tumor cells were inoculated 1–2 days after the last 
fighting. Administration of SSR149415 was made in the 
1st experiment a day before and tumor cell administra-
tion day; in the 2nd experiment — 3 days before, during 
carcinoma cells inoculation day and two next days. 
The hours and days immediately after inoculation are 
thought to be a sensitive period for tumor cells dis-
semination and future growth of metastatic nodules. 
During this period, double and sixfold administration 
of SSR149415 did not change the increased intensity 
of Lewis lung carcinoma cells metastasis in animals 
with anxiety-like behavior irrespective of the route 
of drug administration. These results provide more 
assurance to claim that the previously found enhanc-
ing effect of a single vasopressin administration on the 
process of malignant metastasis is mediated not 
by V1b receptors. In other words, the V1b receptors 
are not involved in tumor cell dissemination and growth 
and the hormone action is not due to its psychotropic 
behaviorally inhibiting effect. 
In this situation V1a receptors preserve their appeal 
to researchers as possible mediators of vasopressin 
effect on metastasis. Receptors of this type are located 
in different regions of the brain and blood vessels and 
together with V1b receptors are involved in behavioral 
phenomena [20]. The latter site of action of the vaso-
pressinergic hormone can influence dissemination 
of tumor cells by luminal narrowing of lungs vessels 
under the effect of vasopressin.
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